Fighting Childhood Obesity to Stay Healthy all Over the Life (OBELISK)

对抗儿童肥胖，终生保持健康 (方尖碑)

• 批准号: 10077650
• 金额: $ 48.82万
• 依托单位: BETA TECHNOLOGY LIMITED
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10077650
• 关键词: Fighting; Childhood; Obesity; Stay; Healthy

Obesity rates in late teens have increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetes and cardiovascular disease, premature death and disability. Efficiently fighting adult obesity is difficult but prevention and treatment of obesity have proven to work better at young ages. OBELISK goal is to cut the roots of the pandemic of obesity in Europe targeting children first. OBELISK is focused on elucidating, Predicting, Preventing obesity and bringing Precision medicine for children with obesity. OBELISK medicine is also Participative (4P), leveraging the potential of social innovation through engagement with families, scientific and medical communities, daycare, schools, municipalities, industries to achieve success. OBELISK objectives are: 1/ to bring breakthroughs in the molecular mechanisms by which causative factors interact to drive (or prevent) the transition from normal weight to obesity during childhood and to develop and exploit for prevention and treatment early predictive proprietary tools; 2/ to identify at least 3 novel childhood obesity genes with the prospect of identifying additional drug targets; 3/ to demonstrate the utility of targeted approaches to prevent childhood obesity; 4/ to bring breakthroughs in childhood obesity treatment including a real-life clinical study of a promising existing drug (GLP1R agonist) to reverse obesity in people with mutations predisposing to early severe obesity; 5/ to exploit the project results and disseminate best practices to prevent and treat childhood obesity, implementing education programs and translating OBELISK clinical results into guidelines and proposals for policy makers to change obesity care; 6/ to facilitate networking and exchanges with other actions and projects in order to optimize knowledge and joint activities. OBELISK targeted approach should contribute to decrease by 35% the number of children with obesity becoming adults with obesity.

在欧洲，青少年晚期的肥胖率从1980年的6%上升到32%，对严重肥胖、糖尿病和心血管疾病、过早死亡和残疾的患病率产生了长期影响。有效地对抗成人肥胖是困难的，但预防和治疗肥胖已被证明在年轻时效果更好。方尖碑的目标是削减肥胖症在欧洲流行的根源，首先针对儿童。OBELISK专注于阐明，预测，预防肥胖，并为肥胖儿童提供精准医疗。方尖碑医学也是创新的（4P），通过与家庭，科学和医学界，日托，学校，市政当局，行业的参与，利用社会创新的潜力，以取得成功。方尖碑的目标是：1/在致病因素相互作用的分子机制方面取得突破，（或预防）儿童时期从正常体重向肥胖的转变，并开发和利用预防和治疗早期预测专有工具; 2/识别至少3个新的儿童肥胖基因，并有望识别其他药物靶点的前景; 3/展示预防儿童肥胖症的靶向方法的效用; 4/在儿童肥胖症治疗方面取得突破，包括对一种有前途的现有药物进行现实临床研究（GLP 1 R激动剂）逆转具有易患早期严重肥胖的突变的人的肥胖; 5/利用项目成果，传播预防和治疗儿童肥胖症的最佳做法，实施教育计划，并将OBELISK的临床结果转化为政策制定者改变肥胖症护理的指南和建议; 6/促进与其他行动和项目的联网和交流，以优化知识和联合活动。OBELISK的目标方法应有助于减少35%的肥胖儿童成为肥胖成年人的数量。